NEW YORK (GenomeWeb News) - Vermillion said yesterday that it has regained compliance for listing on the Nasdaq Stock Market by retaining a market value of $35 million for a period of ten consecutive business days.
In August, Nasdaq notified the company, which was called Ciphergen at the time, that it was out of compliance with Nasdaq Marketplace Rule 4310(c)(3) due to insufficient market value.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.